SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 1999 Commission file number: 0-20081 PruTech Research and Development Partnership III - ----------------------------------------------------------------------------- (Exact name of Registrant as specified in its charter) California 77-0129484 - ----------------------------------------------------------------------------- (State or other jurisdiction (I.R.S. Employer Identification No.) of incorporation or organization) One Seaport Plaza, 28th Floor, New York, NY 10292 - ----------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (212) 214-3500 N/A - ----------------------------------------------------------------------------- Former name, former address and former fiscal year, if changed since last report. Item 5 - Other Events PruTech Research and Development Partnership III (the "Registrant") was recently advised by Forest Laboratories, Inc. ("Forest") that Forest has still not responded to the FDA's November 1998 non-approval letter relating to their application for Synapton. As a result, there is no expectation that the Registrant will receive any revenues from its royalty interest in Synapton. The Registrant's royalty positions with Creative BioMolecules, Inc. and Forest, both of which expire in December 1999, are deemed to have no value. As a result, the Registrant has been liquidated in accordance with its partnership agreement. On November 12, 1999 the Registrant made a final liquidating distribution to the Unitholders of $23.26 per unit. As this distribution to the Unitholders represented the final step in the dissolution and liquidation of the Registrant, R&D Funding Corp terminated the Registrant effective November 15, 1999 by filing a certificate of cancellation with the Secretary of State of the state of California. Item 7 - Financial Statements and Exhibits (c) Exhibits 2.1 Letter to Unitholders of PruTech Research and Development Partnership III SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. PruTech Research and Development Partnership III By: R&D Funding Corp A Delaware corporation, General Partner By: /s/ Brian J. Martin Date: November 15, 1999 - ---------------------------------------------- Brian J. Martin President, Chief Executive Officer, Chairman of the Board of Directors and Director for the Registrant By: R&D Funding Corp A Delaware corporation, General Partner By: /s/ Steven Carlino Date: November 15, 1999 - ---------------------------------------------- Steven Carlino Vice President Chief Accounting Officer for the Registrant